Immunogenicity and Safety of a MenACWY-CRM Booster Dose 4-6 Years After Primary Quadrivalent Meningococcal Conjugate Vaccination in Healthy US
Methods. 602 adolescents and adults aged 15-55 years who had received either MenACWY-CRM (N = 301) or MenACWY-D (N = 301) 4-6 years earlier, and a control group of vaccine-naïve participants (N = 102) were enrolled at 37 centers across the US and 701 overall received a single dose of MenACWY-CRM at Day 1, across study groups. Immunogenicity was evaluated pre-vaccination, either 4 or 6 days post-vaccination (sampling subgroups) and 29 days post-vaccination by serum bactericidal activity assay using human complement (hSBA). After vaccination, all participants were to be monitored for 7 days for reactogenicity, 29 days for unsolicited adverse events (AEs), and 6 months for occurrence of medically attended events, AEs leading to withdrawal and serious AEs.
Results. Sufficiency of the immune response to a booster dose of MenACWY-CRM was demonstrated as the lower limit of the 1-sided 97.5% confidence interval for percentages of participants with hSBA seroresponse for each serogroup at 29 days post-vaccination was >75%, both in participants primed with MenACWY-CRM and MenACWY-D. Independent of quadrivalent meningococcal vaccine priming, >93% of participants achieved a seroresponse at day 29 post-booster. By day 6 post-booster, >47% of primed participants achieved hSBA titers ≥1:8 for MenA, >87% for MenC, >93% for MenW and >85% for MenY, and by day 29 almost all primed participants had seroprotective titers across all serogroups. Overall, the vaccine was well tolerated across participants in all 3 groups and no safety concerns were raised.
Conclusion. MenACWY-CRM induced robust boosting in adolescents and adults primed with a quadrivalent meningococcal conjugate vaccine 4-6 years earlier, with an acceptable clinical safety profile.
Funding Saturday, October 6, 2018: 12:30 PM Background. In 2015, the US Advisory Committee on Immunization Practices (ACIP) made a Category B recommendation for serogroup B meningococcal (MenB) vaccines for adolescents 16-18 years. In 2016, MenB caused ~60% of invasive meningococcal disease among US individuals 16-23 years old; however, utilization of MenB vaccines was much lower than other vaccines with Category A recommendations. Therefore, we examined factors associated with awareness and utilization of MenB vaccines.
Methods. An online quantitative survey was fielded among 619 US parents of adolescents aged 16-19 years, recruited from GfK's KnowledgePanel ® in December 2016. Demographics, access to care, decision making, and vaccine use were collected. A population-based weighting method was applied. Four logistic regressions and Classification And Regression Trees (CART) were conducted to examination most influential factors associated with MenB vaccine awareness and utilization.
Results. Of the weighted sample, 57% were unaware of MenB vaccines (Figure 1 ). Results from logistic regression models (Table 1) revealed that awareness was likely associated with gender and race. Parents who obtained a recommendation from HCPs were 4.8 (95% CI: 2.5-9.4) times more likely to vaccinate or intend to vaccinate their adolescent children and 5.7 (95% CI: 2.5-12.9) times more likely have adolescents already vaccinated than those parents who did not receive the recommendation from HCP. Race/ethnicity and insurance type were associated with awareness and vaccine utilization. The results from CART verified that HCPs' recommendation is the most influential factor to predict the vaccination status. Parents' socio-economic status and their relationship with HCPs were among the most influential predictors of awareness of MenB vaccines or interest in learning about MenB vaccines if they were unaware.
Conclusion. MenB awareness and vaccination are associated with parents' socio-economic status and HCPs' recommendation. Even among those unaware, there was a willingness to vaccinate when recommended by an HCP. These data underscore the critical need for robust understanding and consistent implementation of ACIP's Category B recommendation to reduce inequities in MenB vaccine awareness and utilization.
